Marked alteration of glycemic profile surrounding lanreotide administration in acromegaly: A case report

Sho Tanaka1, Akira Haketa1*, Shun Yamamuro2, Toshiko Suzuki1, Hiroki Kobayashi1, Yoshinari Hatanaka1, Takahiro Ueno1, Noboru Fukuda1, Masanori Abe1, Atsuo Yoshino2, Masayoshi Soma1

1Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, and 2Department of Neurological Surgery, Nihon University School of Medicine, Tokyo, Japan

Keywords
Acromegaly, Diabetes mellitus, Lanreotide

*Correspondence
Akira Haketa
Tel.: +81-3-3972-8111
Fax: +81-3-3972-8311
E-mail address: haketa07@gmail.com

J Diabetes Investig 2018; 9: 223–225
doi: 10.1111/jdi.12675

ABSTRACT
Whether somatostatin analogs for acromegaly improve or worsen a patient’s glycemic profile is controversial. A risk of hypoglycemia should be presumed, especially when patients receive insulin therapy, as the package inserts caution. However, a detailed clinical course of such a case has never been reported in research articles. An 80-year-old Japanese female diabetes patient treated with insulin therapy was diagnosed with acromegaly, and the somatostatin analog, lanreotide, was given. On day 4 of lanreotide treatment, repeated hypoglycemia as a result of exogenous insulin arose and the patient required inpatient care. After lanreotide treatment, the total daily insulin dose could be reduced, but her fasting C-peptide level decreased from 1.6 to 0.4 ng/mL, implying improved insulin resistance and impaired endogenous insulin secretion. In the present case, marked alteration surrounding lanreotide administration was observed; careful co-administration with insulin therapy is required, as the package insert cautions.

INTRODUCTION
Acromegaly is an endocrine disorder characterized by overgrowth with subsequent metabolic complications in response to a chronic excess of growth hormone (GH) and insulin-like growth factor-1 (IGF-1)1. Impaired glucose metabolism is a frequent complication.

Lanreotide, a somatostatin analog (SSA), is frequently used for acromegaly. However, whether SSAs improve or worsen glycemic profiles is controversial2–4. Furthermore, although the package insert clearly cautions the risk of hypoglycemia, especially in patients receiving insulin therapy, a detailed clinical course of such a case has never been reported in research articles5.

Herein, we report an acromegaly patient whose glycemic profile was markedly altered after lanreotide administration.

CASE REPORT
An 80-year-old Japanese woman with diabetes mellitus presented at the Nihon University Itabashi Hospital, Tokyo, Japan. Diabetes was diagnosed at 50 years-of-age, which was finally treated with multiple daily insulin injections (MDII) from 72 years-of-age onwards. Glycated hemoglobin was 7.1%, maintained with 56 units of a total insulin daily dose: 20 units of insulin degludec at bedtime, and 10–14 units of insulin aspart before meals. She did not take any medicine, including oral hypoglycemic agent, other than insulin.

The patient’s body mass index was 22.2 kg/m² (height 153 cm, weight 52 kg). Her vital signs were unremarkable. Acromegalic facies and enlarged extremities were observed. Cushingoid signs were not evident. Hormones under the above MDII were measured (Table 1). GH and IGF-1 were pathologically high. Adrenocorticotropic hormone and cortisol were not consistently high, and midnight serum cortisol was atypical for Cushing disease (Table 2). Magnetic resonance imaging showed a tumor on the pituitary, and the patient was diagnosed with acromegaly. Pituitary hormones, other than GH, were unremarkable in pituitary function tests. Acute octreotide suppression test was positive.

An intramuscular injection of 90 mg lanreotide was given, and blood glucose declined (Figure 1). The patient continued MDII as aforementioned, and was admitted because of repeated hypoglycemia on the fourth day. Insulin injections were temporarily suspended, and dextrose was intravenously infused to prevent a hypoglycemic attack. Levels of immunoreactive insulin (0.2 μU/mL; measured using Roche's Cobas 8,000 modular analyzer, which does not detect exogenous insulin analogs),
serum C-peptide (0.1 ng/mL) and plasma glucose (1.4 mmol/L) implied exogenous insulin-induced hypoglycemia. With this hypoglycemic event as a trigger, the patient hoped to avoid use of antidiabetic medicine with hypoglycemic risk, including insulin. To maintain glucose without hypoglycemia, vildagliptin (100 mg/day) and metformin (500 mg/day) were given instead of insulin. However, a response to an oral hypoglycemic agent was not achieved. Then, 4 units of insulin aspart before each meal was restarted, and the patient’s preprandial blood glucose (an average of glucose levels before each meal) was maintained.

With vildagliptin (100 mg/day), hormones were measured on the seventh day, but the results of serum and urine C-peptide were obtained on the 11th day (Table 1). GH and IGF-1 were naturally lower; meanwhile, serum and urine C-peptide showed low values.

**DISCUSSION**

Acromegaly is an endocrine disease characterized by inappropriate systemic overgrowth. Impaired glucose metabolism is a frequent complication, with half of patients showing glycemic intolerance. SSA is frequently used, but whether SSA improves or worsens glycemic profiles is controversial. Indeed, lanreotide multifariously modified glucose in 30–40% of patients. Its risk of causing hypoglycemia, especially in patients receiving insulin therapy, is clinically well-recognized. However, a detailed clinical course of such a case has never been reported in research articles.

The 44-unit reduction in total insulin daily dose implied a marked alteration of this patient’s diabetes. As insulin secretion was impaired after administration, this improvement was attributed to increasing insulin sensitivity. GH influences glucose metabolism through two contradictory pathways; while IGF-1 mediated by GH plays a similar role to insulin, GH interferes with insulin receptor substrate 2, phosphatidylinositol 3-kinase and Akt activation, resulting in insulin resistance, a dominant factor for glucose intolerance in acromegaly. Similar to somatostatin inhibiting hormone release through binding somatostatin receptor (SSTR) 1–5, lanreotide binds SSTR2 strongly and SSTR5 weakly, to inhibit hormone release, including GH, thus modifying glucose. Disease controllability and a lower body mass index are predictors for glycemic improvement in lanreotide therapy for acromegaly. The early normalization of IGF-1 and non-obesity in the present case did not conflict with an improvement. Furthermore, the patient’s race was also possibly implicated in the her response to treatment: East Asians have high insulin sensitivity, suggesting improved insulin resistance can be more easily attained.

The impaired insulin secretion after lanreotide administration was also of interest. Low levels of serum and urine C-peptide imply lanreotide altered the patient’s diabetes to an insulin-dependent state. Serum glucagon remained unaltered; however, it was presumed that lanreotide severely impaired β-cell function through SSTR5. While it is well recognized that pasireotide binds with high affinity to SSTR5 and causes hyperglycemia, lanreotide also has certain affinities to SSTR5. From another angle, the decreased C-peptide level to that before lanreotide treatment probably meant decreased insulin resistance. Ohkura reported that ‘20 / (fasting C-peptide × fasting plasma glucose)’ correlates well with insulin resistance estimated by a glucose infusion rate evaluated by euglycemic clamp. Although insulin therapy makes a fair judgment difficult, the regression equation in that article estimated the glucose infusion rate of the present case at 5.64 mg/kg/min (before) and 18.38 mg/kg/min (after).

The present case included several limitations. First, with regard to an oral glucose tolerance test, the standard diagnostic method for acromegaly, tests on insulin resistance and glucose stimulated insulin secretion were not carried out, because severe hyperglycemia was predicted based on the high-dose insulin requirement of the patient’s MDII regimen. Second, the transient withdrawal of insulin injections and environmental factors, such as physical activity and diet, that become altered on admission, might have affected the clinical course. Therefore, the reduction observed in the total insulin daily dose might not simply reflect the influence of lanreotide.

**Table 1** | Hormones regulating glucose surrounding lanreotide administration

|       | Before   | After   |
|-------|----------|---------|
| Glucose | 7.9      | 8.2     |
| GH     | 8.72     | 3.26    |
| IGF-1  | 403      | 128     |
| Serum C-peptide | 1.6 | 0.4     |
| Urine C-peptide | Not measured | 17.5 |
| Glucagon | Not measured | 134   |
| ACTH   | 83.3     | 54.7    |
| Cortisol | 17.1    | 17.3    |
| TSH    | 0.18     | 0.12    |
| Free T3 | 3.20    | 2.80    |
| Free T4 | 1.84    | 1.62    |

Hormones were examined after overnight fasting, and before and after lanreotide administration. Diabetes was treated with multiple daily insulin injections using 52 units of total insulin daily dose (before) and vildagliptin 100 mg/day (after), respectively. ACTH, adrenocorticotropic hormone; GH, growth hormone; IGF-1, insulin-like growth factor-1; T3, triiodothyronine; T4, thyroxine; TSH, thyroid-stimulating hormone.

**Table 2** | Repeated measurement of adrenocorticotropic hormone and cortisol level

|       | ACTH (9–52 pg/mL) | Cortisol (3.8–18.4 µg/dL) |
|-------|--------------------|--------------------------|
| Morning | 37.0               | 14.2                     |
|        | 83.3               | 17.1                     |
| 18.8    |                    | 66                       |
|        | 29.6               | 13.7                     |
| Midnight| 12.0               | 4.8                      |

Adrenocorticotropic hormone (ACTH) and cortisol were measured at four different early morning fasting times and midnight before lanreotide administration.
Importantly, SSAs should be administered with inpatient medical care to ensure appropriate treatment for any altered glycemic profile, if they are administered to diabetes patients receiving high-dose insulin therapy.

DISCLOSURE
The authors declare no conflict of interest.

REFERENCES
1. Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest 2009; 119: 3189–3202.
2. Caron PJ, Petersen S, Houchard A, et al. Glucose and lipids levels with lanreotide autogel 120 mg in treatment-naïve patients with acromegaly: data from the PRIMARYS study. Clin Endocrinol (Oxf) 2016; 86: 541–551.
3. Couture E, Bongard V, Maiza JC, et al. Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide. Pituitary 2012; 15: 518–525.
4. Colao A, Auriemma RS, Savastano S, et al. Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study. J Clin Endocrinol Metab 2009; 94: 2907–2914.
5. Tolis G, Angelopoulos NG, Katounda E, et al. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. Neuroendocrinology 2006; 83: 249–257.
6. Alexopoulos O, Bex M, Kamenicky P, et al. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary 2014; 17: 81–89.
7. Sasaki-Suzuki N, Arai K, Ogata T, et al. Growth hormone inhibition of glucose uptake in adipocytes occurs without affecting GLUT4 translocation through an insulin receptor substrate-2-phosphatidylinositol 3-kinase-dependent pathway. J Biol Chem 2009; 284: 6061–6070.
8. Ren SG, Taylor J, Dong J, et al. Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J Clin Endocrinol Metab 2003; 88: 4239–4245.
9. Kodama K, Tojjar D, Yamada S, et al. Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. Diabetes Care 2013; 36: 1789–1796.
10. Kumar U, Sasi R, Suresh S, et al. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 1999; 48: 77–85.
11. Silverstein JM. Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly. Pituitary 2016; 19: 536–543.
12. Ohkura T, Shiochi H, Fujioka Y, et al. 20/((fasting C-peptide x fasting plasma glucose) is a simple and effective index of insulin resistance in patients with type 2 diabetes mellitus: a preliminary report. Cardiovasc Diabetol 2013; 12: 21.